Akoya Biosciences Inc. (AKYA)
Akoya Biosciences Statistics
Share Statistics
Akoya Biosciences has 49.82M shares outstanding. The number of shares has increased by 0.87% in one year.
Shares Outstanding | 49.82M |
Shares Change (YoY) | 0.87% |
Shares Change (QoQ) | 0.51% |
Owned by Institutions (%) | 24.51% |
Shares Floating | 20.76M |
Failed to Deliver (FTD) Shares | 11.15K |
FTD / Avg. Volume | 1.64% |
Short Selling Information
The latest short interest is 1.6M, so 3.23% of the outstanding shares have been sold short.
Short Interest | 1.6M |
Short % of Shares Out | 3.23% |
Short % of Float | 3.23% |
Short Ratio (days to cover) | 13.43 |
Valuation Ratios
The PE ratio is -2.04 and the forward PE ratio is -4.74. Akoya Biosciences's PEG ratio is 0.09.
PE Ratio | -2.04 |
Forward PE | -4.74 |
PS Ratio | 1.39 |
Forward PS | 0.5 |
PB Ratio | 14.9 |
P/FCF Ratio | -2.43 |
PEG Ratio | 0.09 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Akoya Biosciences.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.61, with a Debt / Equity ratio of 1.05.
Current Ratio | 2.61 |
Quick Ratio | 1.78 |
Debt / Equity | 1.05 |
Debt / EBITDA | -0.21 |
Debt / FCF | -0.17 |
Interest Coverage | -4.48 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $398.4K |
Profits Per Employee | $-270.07K |
Employee Count | 205 |
Asset Turnover | 0.65 |
Inventory Turnover | 1.39 |
Taxes
Income Tax | 146K |
Effective Tax Rate | -0.26% |
Stock Price Statistics
The stock price has increased by -69.05% in the last 52 weeks. The beta is 1.32, so Akoya Biosciences's price volatility has been higher than the market average.
Beta | 1.32 |
52-Week Price Change | -69.05% |
50-Day Moving Average | 2.03 |
200-Day Moving Average | 2.42 |
Relative Strength Index (RSI) | 30.38 |
Average Volume (20 Days) | 679.6K |
Income Statement
In the last 12 months, Akoya Biosciences had revenue of 81.67M and earned -55.37M in profits. Earnings per share was -1.12.
Revenue | 81.67M |
Gross Profit | 47.88M |
Operating Income | -46.73M |
Net Income | -55.37M |
EBITDA | -37.14M |
EBIT | -44.79M |
Earnings Per Share (EPS) | -1.12 |
Balance Sheet
The company has 11.78M in cash and 7.96M in debt, giving a net cash position of 3.81M.
Cash & Cash Equivalents | 11.78M |
Total Debt | 7.96M |
Net Cash | 3.81M |
Retained Earnings | -285.44M |
Total Assets | 125M |
Working Capital | 47.29M |
Cash Flow
In the last 12 months, operating cash flow was -44.1M and capital expenditures -2.46M, giving a free cash flow of -46.56M.
Operating Cash Flow | -44.1M |
Capital Expenditures | -2.46M |
Free Cash Flow | -46.56M |
FCF Per Share | -0.94 |
Margins
Gross margin is 58.62%, with operating and profit margins of -57.22% and -67.79%.
Gross Margin | 58.62% |
Operating Margin | -57.22% |
Pretax Margin | -67.61% |
Profit Margin | -67.79% |
EBITDA Margin | -45.47% |
EBIT Margin | -57.22% |
FCF Margin | -57.01% |
Dividends & Yields
AKYA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for AKYA is $3, which is 123.9% higher than the current price. The consensus rating is "Hold".
Price Target | $3 |
Price Target Difference | 123.9% |
Analyst Consensus | Hold |
Analyst Count | 7 |
Scores
Altman Z-Score | 0.27 |
Piotroski F-Score | 4 |